Lyell ImmunopharmaLYEL
LYEL
About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Employees: 300
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
17% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 7 (+1) [Q2]
10.9% more ownership
Funds ownership: 51.61% [Q1] → 62.51% (+10.9%) [Q2]
0% more capital invested
Capital invested by funds: $81.8M [Q1] → $81.8M (+$89.3K) [Q2]
40% less funds holding
Funds holding: 113 [Q1] → 68 (-45) [Q2]
73% less call options, than puts
Call options by funds: $45K | Put options by funds: $165K
81% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 52
98% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 57
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
7%
downside
Avg. target
$10
7%
downside
High target
$10
7%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor | 7%downside $10 | Neutral Maintained | 24 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2025. Lyell's lead clinical program, LYL314, is a next-generation autologous dual-targeting CD19/CD20 CAR T-cell product candidate under evaluation in PiNACLE, a single-arm pivotal trial enrolling patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) in the 3L+ setting and in a Phase 1/2 study in the 2L setting.
Neutral
GlobeNewsWire
1 month ago
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million.
Positive
Seeking Alpha
1 month ago
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Lyell Immunopharma's LYL314 CAR-T therapy shows high, durable response rates in 3rd-line + Large B-Cell Lymphoma patients. The company has initiated a phase 3 trial for LYL314 in 3rd-line + LBCL following positive FDA feedback after the end-of-phase 1 meeting. A key upcoming catalyst is the planned phase 3 trial in 2nd-line + LBCL patients, expected to begin in early 2026.
Neutral
GlobeNewsWire
2 months ago
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET.
Neutral
GlobeNewsWire
2 months ago
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced positive new clinical data from the multi-center Phase 1/2 trial of LYL314, including data from patients with large B-cell lymphoma (LBCL) treated in the third- or later-line (3L+) setting. LYL314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA that is in development for patients with relapsed and/or refractory (R/R) LBCL. In patients treated in the 3L+ setting (N = 25), LYL314 continued to demonstrate robust clinical responses, with an 88% overall response rate and a 72% complete response rate. Of the 3L+ patients who achieved a complete response, 71% remained in complete response at ≥ 6 months. The single-arm pivotal PiNACLE trial, a seamless expansion of the Phase 1/2 trial of patients with R/R LBCL being treated in the 3L+ setting, is underway.
Neutral
GlobeNewsWire
2 months ago
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities.
Neutral
GlobeNewsWire
2 months ago
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET.
Neutral
GlobeNewsWire
3 months ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025. Lyell's lead clinical program, LYL314 (formerly known as IMPT-314), is an autologous CD19/CD20 dual-targeting CAR T-cell product candidate under evaluation in a Phase 1/2 trial enrolling patients with relapsed and/or refractory large B-cell lymphoma (LBCL). LYL314 was recently granted RMAT designation by the United States FDA in recognition of its potential to address significant unmet needs in patients with aggressive LBCL in the third- or later-line setting.
Neutral
GlobeNewsWire
3 months ago
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an abstract highlighting new clinical data from the Phase 1/2 trial of LYL314 (formerly IMPT-314) in large B-cell lymphoma will be presented as an oral presentation at the International Conference on Malignant Lymphoma (ICML) 2025 taking place in Lugano, Switzerland June 17-21, 2025.
Neutral
GlobeNewsWire
4 months ago
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 (formerly IMPT-314) for the treatment of adult patients with relapsed and/or refractory large B-cell lymphoma after two or more prior lines of therapy. LYL314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19‑targeted CAR T-cell therapies for the treatment of aggressive large B-cell lymphoma (LBCL).
Charts implemented using Lightweight Charts™